T-Dxd Improves Survival in Gastric/GEJ Cancer, but Increases Toxicity

Summary: A recent study shows that a drug called T-Dxd helps people with stomach (gastric) cancer live longer. Compared to regular chemotherapy, T-Dxd lowers the risk of death by 33% and stops the cancer from growing in many patients. However, there is a major catch: the drug has tough side effects. Almost all patients (98%) experienced side effects, and nearly half had severe ones. Doctors say it is a powerful tool, but patients face a tough trade-off between fighting the cancer and dealing with the drug's harsh effects.

For more details, see rssapp-gastroenterologyadvisor-com at gastroenterologyadvisor.com/news/t-dxd-improves-survival-in-gastric-gej-cancer-but-increases-toxicity/ (opens in new tab)